Testing a lower dose of arthritis medication given twice yearly

This trial is testing whether a lower dose of Rituximab—a medication that helps control rheumatoid arthritis by targeting specific immune cells—can work just as well as the standard higher dose. Currently, people with RA typically receive the medication once every six months at a higher strength. Researchers want to see if using less of the medication every six months might work equally well while potentially reducing side effects.

Doctors are concerned about long-term safety risks and costs associated with the standard dose of this medication, including increased infection risk and weakened immunity. Early research suggests that a lower dose might control arthritis just as effectively, which could make treatment safer and more affordable.